|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||126.53 - 127.85|
|52-week range||100.39 - 149.25|
|Beta (5Y monthly)||1.00|
|PE ratio (TTM)||59.51|
|Forward dividend & yield||0.96 (0.76%)|
|Ex-dividend date||23 Jun 2023|
|1y target est||N/A|
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zimmer (ZBH) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Investors continue to be optimistic about Integra Lifesciences (IART) based on the prospect of its CSS segment and ample liquidity to support M&A strategies.
ZBH vs. RMD: Which Stock Is the Better Value Option?
Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.
Encompass Health (EHC) remains well-poised for growth, attributable to expanding patient admissions, robust expansion endeavors and strong cash-generating abilities.
Investors continue to be optimistic about Globus Medical (GMED) based on the strong performances across geographies and the pending NuVasive acquisition.
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Investors are optimistic about Zimmer Biomet (ZBH) on continued procedure recovery, solid execution and increasing traction around innovations.
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Abbott (ABT) continues to make good progress, increasing manufacturing production and recovering market share in the Nutrition business.
Stryker, Boston Scientific, Zimmer Biomet and Insulet are part of the Zacks Industry Outlook article.
Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, BSX, ZBH and PODD are well-poised to gain from the favorable factors.
Encompass Health's (EHC) Q1 results reflect improved patient volumes and higher discharge growth. Management estimates 2023 adjusted EPS within $2.94-$3.23, up from the earlier view of $2.87-$3.16.
Does Zimmer Biomet (ZBH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.